BioMarin Pharmaceuticals Inc said it would purchase Dutch drug developer Prosensa Holding NV for about $840 million including milestone payments, aiming to add to its portfolio of drugs to treat rare diseases. BioMarin will offer $17.75 for every Prosensa share and make two milestone payments of $80 million each following U.S. and European approvals for Prosensa's lead drug, drisapersen.
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. Shares of BMRN traded higher by 1.66% or $1.4/share to $85.83. In the past year, the shares have traded as low as $55.04 and as high as $88.23. On average, 1097430 shares of BMRN exchange hands on a given day and today's volume is recorded at 847435.
Prosensa Holding N.V., formerly Prosensa Holding B. Shares of RNA fell by 0.61% or $-0.07/share to $11.44. In the past year, the shares have traded as low as $3.95 and as high as $13.75. On average, 217762 shares of RNA exchange hands on a given day and today's volume is recorded at 110708.
Source
